Breast Cancer Liquid Biopsy Market to Reach USD 2,495 Million by 2032 at 22.5% CAGR

SAN FRANCISCO - April 22, 2026 - PRLog -- Breast Cancer Liquid Biopsy Market Size is projected to reach USD 2,495 Million by 2032, growing at a CAGR of 22.5% from 2023 to 2032. The global Breast Cancer Liquid Biopsy Market accounted for USD 335 Million in 2022, driven by rising demand for non-invasive cancer detection technologies and increasing prevalence of breast cancer worldwide.

The latest Breast Cancer Liquid Biopsy Market Report from Acumen Research And Consulting highlights how advancements in precision diagnostics and early detection methods are accelerating Breast Cancer Liquid Biopsy Market Growth globally.

What is the Breast Cancer Liquid Biopsy Market Size?

The Breast Cancer Liquid Biopsy Market Size was valued at USD 335 Million in 2022 and is projected to reach USD 2,495 Million by 2032, growing at a CAGR of 22.5% from 2023 to 2032.

Breast Cancer Liquid Biopsy Market Statistics

• Market Size (2022): USD 335 Million
• Projected Market Size (2032): USD 2,495 Million
• CAGR (2023–2032): 22.5%
• North America Market Share (2022): Over 35%
• Asia-Pacific Growth Rate: CAGR of 23%
• Circulating Cell-Free DNA Segment Share: Over 47%

Access PDF Sample Report: https://lnk.ua/tTWnx0O7d

Key Drivers of Breast Cancer Liquid Biopsy Market Growth

The Breast Cancer Liquid Biopsy Market Growth is primarily driven by the increasing prevalence of breast cancer, which accounts for nearly 30% of all new cancer diagnoses in women globally. This growing disease burden is accelerating the need for advanced diagnostic solutions.

Liquid biopsy technology is gaining traction due to its non-invasive nature and ability to detect cancer at early stages.

Breast Cancer Liquid Biopsy Market Trends

A key trend shaping the Breast Cancer Liquid Biopsy Market Trends is the growing adoption of circulating biomarkers for accurate and real-time cancer monitoring. These technologies enable clinicians to track disease progression and personalize treatment strategies.

Another major trend in the Breast Cancer Liquid Biopsy Market Analysis is the increasing focus on early detection and precision medicine.

Regional Insights and Market Analysis

North America dominates the Breast Cancer Liquid Biopsy Market Share, accounting for more than 35% of the global market in 2022. This leadership is supported by advanced healthcare infrastructure and high adoption of innovative diagnostic technologies.

Meanwhile, Asia-Pacific is emerging as the fastest-growing region, with a projected CAGR of 23%, driven by increasing healthcare investments, rising awareness, and expanding access to advanced cancer diagnostics.

Read full news at Globenewswire: https://www.globenewswire.com/news-release/2023/06/28/2696395/0/en/Breast-Cancer-Liquid-Biopsy-Market-Forecast-Future-Outlook-and-Industry-Projections-2032.html